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Abstract 
In 2016, a review of modeled cost-effectiveness studies published in the Journal of Medical Economics between January 2015 and 
December 2015 was presented in INNOVATIONS in Pharmacy. The purpose of this review, together with similar reviews for studies 
published in calendar 2015 in Value in Health and Pharmacoeconomics, was to consider whether these modeled claims for cost-
effectiveness met the standards of normal science: were the claims made credible, evaluable and replicable? A total of 32 studies were 
identified. None of the studies presented their claims or projections in an evaluable form and none suggested how they might be 
evaluated. None met the standards of normal science. The claims made for cost-effectiveness were either impossible to verify, or if 
potentially verifiable, were not presented in an evaluable form. The studies lacked credibility. There was no basis for assessing whether 
the claims were right or even if they were wrong. The purpose of the present review which covers cost-effectiveness studies published 
in the Journal of Medical Economics between January 2016 and December 2016 is to revisit this question of the credibility of the claims 
made against the standards of normal science. A total of 40 cost-effectiveness studies were identified. Although 14 had a timeframe 
of 5 years or less and hand the potential to provide short-term evaluable claims, none addressed the issue of claims evaluation and the 
possible protocols that would support empirical assessment. Of the balance, 19 presented results as unevaluable lifetime modeled 
claims. The conclusions from the 2016 review remain unchanged. 
 
Keywords: Journal of Medical Economics, systematic review, cost-outcomes, imaginary worlds, evaluation 
 
 
Introduction 
Some 12 months ago a commentary was published in 
INNOVATIONS in Pharmacy reviewing, from the perspective of 
the standards of normal science, modeled technology 
assessment claims published in the Journal of Medical 
Economics from January 2015 to December 2015 1. This 
systematic review concluded that of the 32 cost-effectiveness 
studies reviewed, none presented their claims or projections 
in an evaluable form and none suggested how they might be 
evaluated. None met the standards of normal science. The 
claims made for cost-effectiveness were either impossible to 
verify, or if potentially verifiable, were not presented in an 
evaluable form. The studies lacked credibility and were best 
seen as constructed imaginary worlds. There was no basis for 
assessing whether the claims were right or whether they were 
wrong, and in the majority of cases they would never know, as   
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the timeframe for the analysis guaranteed that the claims 
were immune to failure. Reviews of studies published in 
Pharmacoeconomics and Value in Health over the same  
calendar 2015 period came to the same conclusion 2 3.  
 
The Journal of Medical Economics review pointed out that this 
lack of scientific credibility is a major concern. If medical 
economics is to advance through the formulation and testing 
of hypotheses, then editors of journals should consider 
whether or not to set standards for the acceptance of 
publications to include the requirement for evaluable claims 
and the results of claims assessment. If this is not acceptable, 
then it should be made clear that published papers are simply 
imaginary worlds or thought experiments. 
 
These reviews of published studies are part of a series of 
commentaries in INNOVATIONS in Pharmacy over the last 12 
months that have focused on the evidentiary standards for 
claims assessment required or recommended by technology 
assessment agencies such as the National Institute for Health 
and Care Excellence (NICE) in the UK and the Pharmaceutical 
Benefits Advisory Committee (PBAC) in Australia, professional 
groups such as the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) and the 
Academy of Managed Care Pharmacy (AMCP) in the US and 
independent research groups such as the Institute for Clinical 
and Economic Review (ICER) 4 5 6 7 8 9 10. The common theme 
in these commentaries, and papers published earlier in the 
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Journal of Medical Economics in a special supplement, is that 
the standards proposed and accepted in health technology 
assessment in the construction of non-evaluable claims should 
be seen as pseudoscience; as intelligent design rather than 
natural selection 11 12 13. 
 
In case this characterization might appear as an unnecessarily 
harsh judgement on standards that have been in place for 30 
years or more and which have generated literally thousands of 
published, peer review studies and evaluations by technology 
assessment groups, the commentaries recently pointed to the 
latest version of the guidelines released in March 2017 by the 
Canadian Agency for Drugs and Technologies in Health 
(CADTH). The CADTH guidelines made it quite clear that the 
technology assessment framework is not to be judged by the 
standards of normal science14 15. Rather, CADTH guidelines are 
designed to set criteria for the construction of imaginary 
worlds or simulations to support cost-outcomes claims; to 
‘inform’ health system decision makers, not to test 
hypotheses. Presumably, within disease areas and for specific 
product comparisons, this additional modeled information will 
be added to the imaginary modeled claims already published 
or submitted to other agencies for the same or similar 
products.  
 
The purpose of this second review of cost-effectiveness 
studies published in the Journal of Medical Economics is to 
consider whether the standards of normal science continue to 
be put to one side, with the Journal continuing to accept 
simulated, non-evaluable claims generated by imaginary 
worlds. The period covers January 2016 December 2016. This 
review follows on one recently published which revisited cost-
effectiveness claims in Value in Health for studies published 
between January 2016 and December 2016 16. This will be 
followed in a forthcoming commentary that will revisit studies 
published in the same time period in Pharmacoeconomics. 
 
Methods 
A systematic review, following the PRISMA-P checklist (MeSH 
terms ‘cost’, ‘cost effectiveness’ , ‘Markov’, ‘QALY’) of all 
papers published in the Journal of Medical Economics in 
calendar 2016 was undertaken 17. In order to judge whether 
the modeled claims presented met the standards of normal 
science four questions were considered: 
 
• Is the study model capable of generating testable 
claims? 
• Did the study attempt to generate testable claims? 
• Did the study suggest how the claims might be 
evaluated? 
• Did the study caution readers as to the implications 
of generating non-testable claims? 
 
Each author independently reviewed the selected studies with 
consensus agreement reached on the assessment. 
 
A testable claim was defined as one that could be evaluated 
empirically in a timeframe relevant to the needs of a formulary 
committee (ideally a period of 2 to 3 years). This period was 
chosen because a testable claim was seen as provisional. A 
product or device could, in this context, be accepted by a 
committee for formulary listing, but subject to an agreement 
with the manufacturer to report back to the committee with 
evidence to support the claims made. These claims could be 
for product comparative effectiveness, for the impact of the 
product on resource utilization or some combination of these 
to support a claim for incremental cost-effectiveness. The 
claim for comparative effectiveness could encompass clinical 
endpoints as well as those captured as patient reported 
outcomes (PROs).   
 
In judging whether or not a model might support testable (1.e., 
falsifiable) claims, even if the possibility was not considered by 
the authors(s), three characteristics of the model are 
important. These are (i) the modeling framework, (ii) the 
choice of primary outcome measure; and (iii) the time frame 
for the model.  A Markov or discreet event simulation model 
with a lifetime perspective and with discounted cost per QALY 
claims as the primary endpoints would be one where 
comparative claims would be impossible to evaluate. There is 
no chance of falsification, feedback to decision makers or 
replication.  It would be assessed as immune to failure. Against 
this, a simple, trial-based decision model with a timeframe of 
12 to 18 months with claims expressed in clinical (including 
PRO) and resource utilization endpoints would be open to 
hypothesis testing and feedback to a formulary committee. 
Even with a short-term time horizon, however, the choice of 
outcome may not be evaluable outside of a protocol-driven 
observational study.  If health care systems do not collect 
specific QALY measures on an ongoing basis then it is 
impossible to evaluate cost-per-QALY willingness-to-pay 
threshold claims from integrated data bases. This assumes, of 
course, that the QALY measure that might be collected is 
consistent with the measure utilized in the simulation model.  
 
While claims may be potentially evaluable, what is typically 
missing in modeled claims is any direction as to how the claims 
might be assessed in treatment practice. Presenting the same 
model that has been re-formulated for different markets and 
different countries, with the model consistently generating 
positive claims for a sponsor’s product seems rather pointless 
in the absence of a protocol that proposes how the modeled 
claims can be evaluated. This is a feature conspicuous by its 
absence in technology assessment submission guidelines.    
 
At the same time, this evaluation also searched for systematic 
reviews published in calendar 2016. Two questions were 
considered relevant: 
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• Did the systematic review of economic evaluations 
address the issue of the credibility, evaluation and 
replication of clinical claims in the respective 
modeled economic evaluations? 
• Did the systematic review recommend (or caution 
against) accepting the claims from the modeled 
economic evaluations as the basis for formulary 
decisions? 
Finally, the review considered whether or not the cost-
effectiveness study was funded or supported by a 
pharmaceutical or device manufacturer. The question 
addressed was whether or not the results of the cost-
effectiveness modeling supported the manufacturer’s 
product. 
 
Results 
The review identified 40 cost-effectiveness studies (Table 1) 
together with one systematic review of economic models in 
moderate-to-severe asthma and COPD 18.  
 
Economic Models 
None of the studies met the standards of normal science in 
providing evaluable and replicable claims in a form that could 
be supported by a claims assessment protocol. Overall, 19 of 
the 40 studies (47.5%) presented their claims in a lifetime 
model framework 19 22 24 26 27 28 29 30 31 32 34 35 36 40 42 44 45 46 53 56.  In 
addition, if we take a cutoff of 6 years or more in the model 
timeframe, a further seven models would be considered to 
have non-evaluable claims 37 38 49 50 51 54 57. The balance of the 
models with a timeframe of 5 years or less had the potential to 
generate or did produce claims that were potentially evaluable 
20 21 23 25 33 39  41 43 46  47 48 52  55 58. 
 
Among those models that presented a lifetime framework for 
generating imaginary claims, 12 utilized a Markov framework 
24 29 30 31 32 36 35 40 44 45 46 56. A further 3 studies utilized the lifetime 
IMS CORE diabetes model 22 26 42. In addition,  4 studies utilized 
a Markov framework for timelines of  10, 25 and 70 years 
together with two studies utilizing the Cardiff Diabetes Model 
for 40 year time horizons  51 38 50 49 54 57 .  In total, therefore, 26 
of the 40 economic evaluations (65.0%) presented modeled 
claims that were immune to failure given the timeframe of the 
model.  
 
In terms of the questions raised: 
 
• Two thirds of the published economic evaluations 
failed to present credible claims that met the 
expected standards of normal science in presenting 
claims for cost-effectiveness that were potentially 
evaluable and replicable 
• None of the studies attempted to present evaluable 
claims, although by default a handful of studies 
presented claims that could be evaluated 
• None of the studies considered how their claims, 
even if potentially evaluable, could be assessed in 
treatment practice  
• None of the studies cautioned the reader that their 
claims might not be evaluable and that the reader 
would have no idea if they were right, wrong or 
potentially misleading 
Systematic Review 
The Einarson et al systematic review of models in moderate-
to-severe asthma and COPD identified 53 articles, 14 of these 
were for patients with asthma and 39 in COPD. Models were 
defined under three heads: (i) prospective trial based models 
(8); (ii) predictive decision models (27); and (iii) retrospective 
patient record models.  
 
Key points noted in summarizing the results were: 
 
• Markov models accounted for 22 of the 27 
decision models 
• Among the Markov asthma models: 
o only 3 reported validation of some sort, 
but most provided no details 
o two used a time period of 12 weeks, 
seven used 1 year, one used 10 years, six 
used a lifetime 
o ten examined inhaled corticosteroids and 
9 omalizumab 
o nine were sponsored by pharmaceutical 
companies, 3  were not stated and 2 
were public sector (NCE, National Heart 
and Blood Institute) 
• Among the asthma related  pharmacoeconomic 
studies 11 used RCTs as primary source for clinical 
data 
• Overall, among the asthma models results varied 
widely: omalizumab was found to be cost-
effective in 9 out of 14 studies but not cost-
effective in 5  
• Among the COPD models: 
o Thirty out of 39 were sponsored by the 
pharmaceutical industry 
o Nineteen models did not mention any 
validation process 
o Thirteen of the studies used a time frame 
between 3-5 years, 10 used a time frame 
of 1 year 
o A Markov model was used in 19 studies 
The key point noted in the discussion was that study 
parameters for the most part were not validated: face validity 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                            2017, Vol. 8, No. 3, Article 13                     INNOVATIONS in pharmacy   4 
 
was most common while internal, external and predictive 
validity were largely absent.  
 
In terms of the two questions raised in respect of this 
systematic reviews of modeled claims: 
 
• The review did not address the question of 
the credibility of the modeled claims, et 
alone issues of whether the claims were 
evaluable and replicable  
• The review did not caution the reader that in 
accepting the claims made that they did not 
meet the standards expected of normal 
science as inputs to the formulary evaluation 
process 
Discussion 
 
The fact that in those studies funded or sponsored by a 
pharmaceutical or device manufacturer in the Journal of 
Medical Economics support the manufacturer’s product is, 
perhaps, unsurprising. After all, the previous review of 
modeled studies in the Journal of Medical Economics made the 
same observation as has the more recent review of studies in 
Value in Health 1 3 .  Indeed, the more cynical reader may 
wonder why there is any surprise at all. After all, does the 
apparent the lack of any challenge to these published claims 
simply reflect the difficulty, or more appropriately, the 
impossibility of challenging the construction of imaginary 
worlds? Or, does the lack of challenge reflect a lack of interest 
by decision makers in imaginary worlds and their imaginary 
claims? Rather than taking claims at face value, holding to the 
belief that the standards of normal science can be put to one 
side by rejecting hypothesis testing in favor of ‘information 
provision’, decision makers may see these publications as 
marketing exercises that they can put to one side.   
 
Discretion in Modeled Claims 
It is worth recalling the 1994 Editorial in the New England 
Journal of Medicine regarding the discretionary nature of cost-
effectiveness studies and the Journal’s policy on accepting 
such studies for review 19. The position taken was that because 
of the discretionary nature of the methods used to analyze 
cost-effectiveness it is ‘incumbent on authors journal editors 
and the funders of these studies to minimize any source of 
bias’. Two conditions were proposed: (i) any study supported 
by industry must be funded by a grant to a not-for-profit entity 
such as a hospital or a university, not to an individual or group 
of individuals; and (ii)  the Journal must receive written 
assurance that the agreement between the authors and the 
funding company ensures the authors’ independence in the 
design of the study, the interpretation of data and writing of 
the report, and decisions regarding publication, regardless of 
the results of the analysis. Studies will not be reviewed by the 
Journal if any of the authors is receiving a direct salary from 
the sponsoring study or a competing company, or if any author 
has an equity interest in, an ongoing consultancy with, or 
membership on the scientific advisory board of such a 
company, or a related patent pending. 
 
The discretionary nature of both clinical and cost-effectiveness 
claims has continued to be of concern, notably in the wider 
context of integrity in research and publications, including the 
issues surrounding the replication of randomized clinical trial 
(RCT) results. Addressing the question of integrity (How do you 
know it is true?) Buckwalter al al argue that The current high-
stakes research environment has been characterized by an 
increase in plagiarism, falsification or manipulation of data , 
selected presentation of results, research bias, and 
inappropriate statistical analyses where research findings can 
be biased by ‘falsification or manipulation’ 20. A  recent 
Cochrane review of interventions to prevent misconduct and 
promote integrity in research and publication found that 
‘Overall, there is very low quality evidence that various 
methods of training in research integrity had some effect on 
participants’ attitudes to ethical issues but minimal (or short-
lived) effects on their knowledge’ 21.  
 
At the same time, as noted in previous commentaries in 
INNOVATIONS in Pharmacy have been increasing concerns 
over the inability of researchers to replicate the results of 
RCTs.  A Nature survey, reported in May 2016, found that over 
70% of researchers had tried and failed to reproduce other 
experiments and more than half failed to reproduce their own 
experiments 22. At the moment we do not seem to have struck 
a balance between tolerating tentative conclusions and honest 
errors and efforts to improve reproducibility in biomedical 
claims 23 .  
 
Questioning the integrity of published clinical research is 
reinforced by more fundamental claims that most published 
research findings can be shown to be false 24 If this is accepted 
then further doubt is cast on those modeled claims that rely 
on one or two clinical trials (typically the sponsors) or on 
network indirect comparisons between (possibly false?) 
comparator trials to support the models clinical assumptions. 
In the absence of claims replication the clinical evidence base 
may be considered insufficient to support modeled claims for 
formulary listing and pricing. Health care decision makers 
would, as detailed below, be justified in asking for the clinical 
outcomes assumptions to be evaluated and reproduced, 
together with claims made for cost-effectiveness. In the case 
where the modeled claims are immune to failure, those 
sponsoring such claims run the risk of them being ignored and 
rejected out of hand as they fall at the first hurdle for 
establishing their credibility. 
 
Discretion and Imaginary Worlds 
One aspect of modeled claims for cost-effectiveness that was 
not addressed by the Editorial in the New England Journal of 
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Medicine is the apparent disregard for the standards of normal 
science; the acceptance of modeled claims for cost-
effectiveness that are non-evaluable. This is not a question of 
replication, but rather one, as noted in the introduction to this 
review, of immunity to failure. This rejection of these 
standards, as noted in the commentaries disregards standards 
that have been in place for 350 years. The motto of the Royal 
Society (founded 1660; Royal Charter 1662) clearly expresses 
this: nullius in verba (‘take no man’s word for it”). If a modeled 
claim in unable to generate, credible, evaluable and replicable 
claims then it should be rejected. The claims should be seen as 
pseudoscience. A conclusion that is reinforced given the 
discretion and latitude that is open to model builders in 
constructing long-term or lifetime cost-outcomes and cost-
utility models; time horizons that may stretch for decades in 
modeled simulations. Examples detailed in this review would 
include claims generated by the Cardiff Diabetes Model with 
time horizons of that effectively preclude any empirical 
challenge. 
 
Unfortunately, in health technology assessments, as detailed 
again in previous commentaries in INNOVATIONS in Pharmacy, 
agencies and professional organizations such as ISPOR and the 
AMCP, seem determined to keep the door open to standards 
for technology assessment that encourage the construction of 
imaginary worlds. The NICE reference case has been widely 
accepted as the ‘gold standard’. It is, therefore, not surprising 
that journal editors are quite prepared to accept modeled 
claims for competing products and devices that are outside the 
standards of normal science.  
 
Indeed, model builders have considerable latitude even within 
the so called ‘reference case’ to construct modelled lifetime 
comparative claims. Professional groups and technology 
assessment agencies ask the reader to take at face value 
extrapolations beyond the remit of clinical trials. In the present 
review 19 of the 40 studies (47.5%) present their claims in a 
lifetime model 19 22 24 26 27 28 29 30 31 32 35 36 40 42 44 45 46 53 56 . Of these, 
12 utilized a lifetime Markov framework 24 29 30 31 32 36 35 40 44 45 46 
56 . A further 3 studies utilized the lifetime IMS CORE diabetes 
model 22 26 42. In addition, a further 5 studies utilized a Markov 
framework for timelines of 5, 7, 10, 25 and 70 years together 
with two studies utilizing the Cardiff Diabetes Model for 40 
year time horizons 39 51 38 50 49 54 57 . None of these studies 
presented claims that could be evaluated.  
 
 
 
Threshold Values 
Irrespective of the choice of imaginary world, the primary 
purpose of the majority of these studies would appear to be to 
demonstrate that, given the choice of model, its structure and 
input variables, that the claims made for the cost-effectiveness 
of the sponsor’s product can be considered because, unless 
they are shown to be dominant in respect of comparators, the 
cost-per-QALY clams falls with ‘accepted’ or ‘recognized’ 
willingness-to-pay thresholds. The thresholds deemed to be 
appropriate in the various studies vary widely. Some studies 
adopted notional willingness-to-pay thresholds with 
US$50,000 being popular, although, if considered appropriate, 
this could be extended to US$100,000 or US$150,000 to claim 
cost-effectiveness and appropriateness for formulary listing. 
Other studies adopted the NICE thresholds of £20,000 and 
£30,000. For studies based in European treating environments 
a popular threshold value was €30,000 with a few studies 
applying the World Health Organisation (WHO) proposed per 
capita GDP 3-times multiple. It is not clear whether the model 
outcomes determined the threshold value chosen or the 
threshold value determined the model. In any event, the 
argument is moot as the claims for threshold compatibility, 
including applications of probabilistic sensitivity analysis, were 
unevaluable. The focus in all cases appeared to support claims 
for the cost-effectiveness of the sponsor’s product. Whether 
this reflects publication bias is unknown. We have no idea of 
how many other, potentially competing, modeled claims were 
developed which have not been or have yet to be published. 
 
Given the popularity of published constructed claims that 
conclude that a product is cost-effective, there is surprisingly 
perhaps no consensus on the use of threshold values, what 
thresholds represent and the construction of threshold 
values25. Questions on how we might value health 
improvements and the opportunity cost of budgetary 
decisions might be more illuminating if we put to one side 
constructed and unevaluable incremental cost per QALY claims 
and focused instead on claims that are evaluable and can be 
reported on to health decision makers in a meaningful 
timeframe. As it stands, and has been pointed out again in 
previous INNOVATION in Pharmacy commentaries, there is no 
agreed standard for measuring utilities for cost-per-QALY 
claims and there is unlikely to be one. Although there are a 
number of generic and disease-specific instrument that have 
been promoted as the basis for utility metrics, clinical trials are 
typically not powered for utility endpoints. As a result the 
imaginary lifetime models will go to the literature to justify the 
choice of utility metric. As well, at least in the US, there is little 
interest in QALY claims and willingness to pay thresholds. The 
exception here being the modeled (yet unevaluable) claims, 
typically from a long-term or lifetime perspective, that have 
been promoted by the ICER to support recommendations for 
the ‘appropriate’ pricing of pharmaceutical products.  
 
It is also worth noting that NICE, in attempting to move to a 
more ‘flexible’ version of the EQ-5D (the ‘reference case’ 
mandated instrument), adopting the EQ-5D-5level instrument 
as a successor to the EQ-5D-3level version has found that the 
two generate different utility profiles and it is not possible to 
crosswalk from the EQ-5D-3L to the EQ-5D-5L. This illustrates 
a more general point, and a strong argument for abandoning 
cost-per-QALY claims, that different instruments generate 
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different results. Achieving a willingness-to-pay cost per QALY 
threshold with one instrument is no guarantee that an 
alternative, yet equally valid, instrument will come to the same 
conclusion.  
 
Comorbidities 
As noted also in previous commentaries, the presence of 
comorbidities and their potential impact on outcomes, costs 
and compliance is typically overlooked in modeled long-term 
claims for cost effectiveness. Given the likelihood of older 
patient groups presenting with one or more comorbidities this 
is a significant oversight by model builders. This is recognized, 
for example, in the Lobotesis et al assessment of combination 
stent-retriever thrombectomy in acute ischemic stroke 59. The 
authors caution that there may be limitations in relation to 
resource use data where acute and long term costs are taken 
from a study based on patients with atrial fibrillation and an 
average age of 80 years. Apparently, these patients are older 
than those in the base case clinical study used; they also suffer 
from atrial fibrillation with possible additional comorbidities. 
 
Assistance and Persistence 
A further issue with modeled claims is the treatment of 
adherence and persistence with therapy. This is seldom 
acknowledged in claims made, although the fact that in many 
disease areas only a minority of patients are compliant after 
two to three years from index prescription will presumably 
impact long-term claims. One exception here is the 
qualification in the application of the CORE diabetes model 
that the model does not take into account ‘potential 
differences between the respective treatments in adherence 
and persistence that can influence both effects and costs’. As 
noted in previous commentaries, it may seem pointless to 
model over (in this case) 50 years when patients have possibly 
long-ceased to persist with the therapy 26. Also, it should be 
noted, the possible impact of new products entering the type 
2 diabetes market and consequent therapy switching is also 
not considered. 
 
Peer Reviews of Imaginary Worlds 
The resources devoted by NICE and other agencies to the 
assessment of a manufacturer’s modeled reference case cost-
utility claims stand in contrast to the support given to peer 
reviewers who are asked to evaluate modeled claims for 
journals such as the Journal of Medical Economics and Value in 
Health. Given time constraints for peer review and claims by 
journals that they can offer ‘rapid publication’ and a short 
turnaround of papers (and you can often pay a ‘quick 
expedition fee’ to guarantee an even faster turnaround) 
suggests that, at best, the evaluation of a constructed 
imaginary world will limited. This does not imply any 
dereliction on the part of journal editors or unpaid peer 
reviewers, but is simply a fact of life. Journals do not have the 
luxury of investing resources on a model review to the 
standards of a NICE or PBAC review. 
 
One solution to the peer review question is to establish 
standards for accepting or rejecting modeled claims for cost-
effectiveness: to ask that the paper meet two acceptance 
criteria: (i) that the claims are evaluable in a timeframe that is 
meaningful for feedback to health system decision makers; 
and (ii) that the model claims are supported by a protocol that 
details how the claims are to be evaluated in treatment 
practice. Perhaps as a first step journal editors (and certainly 
formulary committees) should reject any manuscript that 
begins with ‘A lifetime Markov model was ….’. 
 
Qualified Support 
In a few cases modeled claims comparisons provide only 
qualified support for the sponsor’s product. This typically 
occurs when the modeled lifetime cost-per-QALY estimates 
exceed notional willingness-to-pay thresholds. Consider, for 
example, the Goeree et al modeled case for nivolumab in non-
small cell lung cancer (NSCLC) in Canada 50. Application of a 
lifetime Markov model or a progression-free survival model 
generated cost-per-QALY estimates versus the comparators 
docetaxel and erlotinib in excess of $140,000. In this case, 
while pointing out that funding has been approved in Canada 
for oncology drugs where the $100,000 willingness to pay 
threshold has been exceeded, the authors emphasize the 
unmet need within NSCLC and that given the perceived NCSLC 
disease burden in Canada, as evidenced by its epidemiological 
profile, nivolumab ‘has the potential to bring significant health 
benefits to patients in comparison to standard chemotherapy 
options (p. 641)’. Nivolumab is seen to ‘represent(s) a major 
advance in disease management’, ‘provides unprecedented 
survival benefits’ and a more favorable adverse event profile. 
These aspects were not, apparently, captured within the 
model framework but should, it can be argued, be factored 
into a willingness to accept cost-per-QALY projections which, 
although immune to failure, are in excess of accepted notional 
thresholds.  
 
Comparing Imaginary Worlds 
It is commonplace for the authors of one long-term imaginary 
world to compare their world with ‘competitor’ imaginary 
worlds. It is not clear what this achieves given that the various 
competitor models also yield claims that are typically immune 
to failure. All that can be achieved are claims that one model 
is more ‘representative’ of an unknown future than another 
model. The potential readers, if they are interested, have no 
basis in the absence of feedback from the evaluation of 
modeled claims to judge whether one model is in any way 
‘superior’ to another. It seems such a pointless exercise. An 
exercise that could, presumably, continue indefinitely as 
manufacturer’s contract with consultants to publish even 
more product-supporting, non-evaluable modeled claims in 
disease and therapy areas. While it might be unreasonable to 
draw to close an analogy with an imaginary world such as that 
represented by Gormenghast, the description of the novels in 
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the series as representing ‘a sprawling, gothic structure’ has a 
certain resonance 27. But perhaps, as noted in a previous 
commentary, we could attempt to close the wardrobe door on 
Narnia and return to the real world of normal science 28 . 
 
Discussions by authors of model ‘limitations’ also point to a 
number of common ‘elements’ that may limit or relegate the 
claims generated by the model. Apart from assumptions (or 
their absence) regarding compliance behavior and 
comorbidities, typical qualifications would include: (i) the use 
of clinical trials to support input values where the trials may 
lack external validity for  input values; (ii) the short-term 
nature of the trial data; (iii) reliance on indirect comparisons 
for clinical endpoints; (iv) costs sourced from the literature 
which may not be those faced by payers; (v) absence of non-
medical or indirect costs; (vi) arbitrary choice of health states 
for treatment progression; (vii) cycle length; (viii) estimation of 
transition probabilities for health states; (ix) assumed future 
patterns of therapy switching; (x) health state utility values; (xi) 
choice of utility measure; and (xii) survivorship profiles. Even 
with this checklist, there is still no objective basis, other than 
evaluating claims made, for declaring the superiority of one 
imaginary construct from another.   
 
Systematic Reviews 
Given the dominance of constructed imaginary worlds in cost-
effectiveness claims, it is reasonable to ask what role 
systematic reviews actually play. Apart, obviously, from the 
review pointing to the diversity, latitude and incompatibility of 
modeled claims within disease areas, it is far from clear that 
such reviews actually perform a useful service. This is in 
contrast to the Cochrane reviews, for example, which are 
anchored in the scientific method to support evidence-based 
medicine. To argue, as the CADTH guidelines so eloquently put 
it, that economic models are not intended to test hypotheses 
but merely to ‘provide information’, raises the question of how 
a formulary committee is to make sense of the diversity and 
incompatibility of the information presented. While it can be 
appreciated that sponsoring economic models to support a 
marketing strategy is an entirely legitimate exercise, the 
presence of highly technical competing yet incompatible 
messages is hardly a positive step forward. Are formulary 
committees expected to undertake a further review of 
systematic reviews? Perhaps, in such a review, a formulary 
committee following advice above to journal editors, should 
immediately reject any study that began ‘A lifetime Markov 
model …’. 
 
The overall impression from the Einarson et al systematic 
review is the difficulty of comparing model results and coming 
to any general conclusions on the imaginary claims for cost-
effectiveness of therapies, either against specific comparators 
or the ‘standard of care’ within either asthma or COPD 18. In 
the case of omalizumab, the results varied widely, in some 
models supporting a cost-effectiveness case with others 
coming to the opposite conclusion. The results for COPD 
presented such variation in the choice of the primary drug and 
its comparators, that it is also difficult, if not impossible, to 
come to any meaningful conclusions that might guide 
formulary decision making.  
 
While the difficulties attendant upon any attempt to ‘herd the 
cats’ in such a variable modelling environment can be 
appreciated, the more substantive issues of credibility, 
evaluation and replication are not addressed in the review. On 
the information presented, there is no evidence that the issue 
of presenting evaluable claims was addressed in any of the 
studies.  While the issue of the face validity of the model was 
apparently addressed in a few studies, internal external and 
predictive validity were largely ignored.  Unfortunately, in 
setting the standards for validation in terms of those proposed 
by ISPOR and the Society for Medical Decision Making (SMDM) 
in their Good Practices Research reports on constructing 
imaginary worlds, the authors overlooked the importance of 
predictive validation as standing outside face validity, internal 
and external validity 29 30. A modeled claim is not to be judged 
on the apparent ‘validity’ of its structure or input assumptions. 
This point was made in a recent critique of modeled claims 11 
12. Predictive validity is not an option in ‘validation’. Failure to 
consider predictive validity puts the standards of normal 
science to one side. Irrespective of any conclusions regarding 
the extent to which a model is considered to have face, 
internal and external validity, the only test (unless we take the 
claims at face value) is empirical: can the claims be validated 
(or at least not falsified) in treatment practice. Otherwise, all 
that Einarson et al have accomplished is to point to the 
variability in constructed imaginary worlds. The paradox is 
that, at least in COPD and to a lesser extent in the asthma 
models, the time frame for many of the models presented is 
one that could support evaluable claims. The possibility that 
the claims presented could be supported by protocols and 
evaluated in clinical practice was not considered. 
 
Potentially Evaluable Claims 
This review has identified a number of studies that have the 
potential to generate evaluable claims. These include the 
Einarson et al 1-year models for  palperidone in schizophrenia 
21 47, the Pettigrew et al colorectal cancer model 23, the Qin et 
al overactive bladder model 25, metastatic colorectal cancer 
model, the Xuan et al duodenal ulcer model 52 and the Goeree 
et al model of opioid-induced constipation 58. While there is 
the potential to generate claims for a range of outcomes and 
summary ICER claims (including cost-per-QALY), none of the 
studies considered how these claims might be evaluated in 
treatment practice. This raises the issue of the role claims 
assessment protocols might have in supporting sponsored and 
other comparative claims for cost-effectiveness. If a formulary 
committee, as proposed in the Minnesota guidelines could 
insist that manufacturers underwrite protocols to support, and 
provide feedback on, clinical and cost-effectiveness claims, 
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then we would go a long way towards, not only abandoning 
the construction of imaginary worlds but addressing issues of 
the replication RCT-based clinical claims 31. 
 
If journals adopted a policy (i) of requiring cost-effectiveness 
claims to be accompanied by an assessment protocol and (ii) 
requiring manufacturers to report on the results of the 
evaluation in a future issue of the journal, this may go some 
way towards alleviating the concerns expressed by the Editors 
of the New England Journal of Medicine. Instead of attempting 
to enforce review (‘entry’) requirements, which would still 
allow the submission of claims based on imaginary worlds 
(e.g., a recent modeled imaginary world review in the Journal 
of the American Medical Association of PCSK9 inhibitors 32), 
the Journal could adopt a protocol policy which would allow 
for manufacturer’ sponsored submissions, but with the 
‘integrity’ of the model claims checked by the need to feed 
back the results of a effectiveness trial or prospective 
observational study. 
 
As an additional check, the Journal could require peer reviews 
of both the initial modeled claims and the report of claims 
evaluation to be published. The former would meet any 
concerns as to the quality and feasibility of the claims 
assessment protocol while the latter would hopefully ensure 
that once published the claims could be assessed in other 
treatment environments, providing an accumulating body of 
evidence to support clinical and outcomes claims for the 
product. 
 
Conclusions 
In the recently published review of modeled cost-effectiveness 
claims in Value in Health, the discussion concluded on a 
pessimistic note: it is unlikely that present practice would be 
overturned. Rather, we could expect a continuation of the 
commitment to creating and publishing claims that are 
‘immune to failure’.  It was pointed out that Richard Dawkins, 
in Unweaving the Rainbow, recognizes our willingness to feed 
on ‘superstition, the paranormal and astrology’. Or, as he 
labels this, our continuing appetite for being ‘Hoodwink’d with 
faery fancy’ 33 . We might extend the reference and argue that 
the ‘imaginary world’ meme is so well entrenched in health 
technology assessment that the biologically valuable tendency 
of individuals to imitate (c.f., the Dawkins’ example of the  
opening of milk bottle tops among European tits or American 
Chickadees) perpetuates the acceptance of lifetime Markov 
models, conferring a survival advantage to those who 
subscribe to the construction of imaginary worlds, supporting 
professional advancement. 
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Table 1 
Imaginary Worlds: Modeled Economic Evaluation Studies in the  
Journal of Medical Economics January 2016 to December 2016 
 
Paper (author) Target 
Population or 
Intervention 
Sponsor or 
Funding(if any) 
Modeling Technique and 
Claims Status 
Did the study 
support the 
sponsor/fund
ers product?  
Claims 
Assessment and 
Credibility 
Chan et al 34  Invasive fungal 
disease in 
acute myeloid 
leukemia or 
myelodysplast
ic syndrome 
No funding 
declared; one 
author an 
employee of 
Merck 
Lifetime decision model of 
posaconazole versus 
fluconazole/itraconazole in 
preventing fungal disease in a 
Hong Kong hospital. Despite 
higher cost, posaconazole 
prophylaxis cost-effective over 
a lifetime horizon by reduction 
in costs of treating invasive 
fungal diseases as costs 
incurred to avoid one IFD well 
under Hong Kong GDP per 
capita.   
The study 
supported the 
Merck 
product 
posaconazole 
Claims presented 
are potentially 
evaluable. While 
the authors 
recommend 
future research 
no 
recommendation 
for  protocols to 
support claims 
assessment to 
meet required 
standards of 
normal science. 
Wan et al 35 Nosocomial 
pneumonia 
caused by 
methicillin 
resistant 
staphylococcu
s aureus 
Pfizer 
Investment Co. 
Ltd 
Trial-based cost-effectiveness 
modeled assessment utilizing 
bootstrap methods to evaluate 
success with linezolid versus 
vancomycinin in four Chinese 
cities. Linezolid dominated 
vancomycin in 1/3 total cases 
with vancomycin dominating in 
only 2% of cases.  
Study 
supported the 
Pfizer product 
linezolid 
Claims presented 
are potentially 
evaluable. While 
the authors 
recommend 
future research 
no 
recommendation 
for  protocols to 
support claims 
assessment to 
meet required 
standards of 
normal science. 
Einarson et al 36 Long-acting 
atypical 
antipsychotics 
in acutely 
relapsed 
schizophrenia  
Janssen-Cilag A 1-year decision sequential 
therapy relapse/non-response 
switching model to assess cost-
effectiveness of aripiprazole 
(ARI-LAI), paliperidone (PP-LAI), 
olanzapine (OLZ-LAI) and 
risperidone (RIs-LAI). 
Outcomes: QALYs, 
hospitalization rates and 
relapse not requiring 
hospitalization. Probability 
sensitivity analysis projected 
PP-LAI dominated ARI-LAI in 
75.8% of 100,000 iterations, 
RIS-LAI in 83.1% and OLZ-LAI in 
95.7%. 
Study 
supported the 
Janssen-Cilag 
product 
paliperidone 
Claims presented 
are potentially 
evaluable. While 
the authors 
recommend 
future research 
no 
recommendation 
for  protocols to 
support claims 
assessment to 
meet required 
standards of 
normal science. 
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Roussel et al 37   Type 2 
diabetes 
patients failing 
glycemic 
control with 
metformin 
monotherapy 
Novo Nordisk Application of IMS CORE 
diabetes model to project 
lifetime clinical outcomes and 
direct costs in a French treating 
environment. Comparisons 
liraglutiude vs  sitagliptin and 
glimepride. Projected ICER of 
€10,275 per QALY gained vs. 
sitagliption and €20,709 per 
QALY gained vs. glimepride 
(both under €30,000 
threshold). 
Study 
supported the 
Novo Nordisk 
product 
liraglutide 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science. 
Pettigrew et al 38 Metastatic 
colorectal 
cancer 
Amgen Canada A net cost impact analysis to 
determine total patient cost of 
panitumumab vs. cetuximab in 
Canada (5 provinces) in 14-20 
week timeframe. Limitations 
noted: no efficacy or QALY 
estimates, and health resource 
utilization from expert opinion. 
Panitumumab cost-saving in all 
scenarios.  
Study 
supported the 
Amgen 
product 
panitumumab 
Claims presented 
are potentially 
evaluable. While 
the authors 
recommend 
future research 
no 
recommendation 
for  protocols to 
support claims 
assessment to 
meet required 
standards of 
normal science 
Moshyk et al 39 Chronic 
hepatitis C 
genotype 3 
Bristol-Myers 
Squibb (BMS) 
A Markov lifetime cost-utility 
model replicating the natural 
history of hepatitis C and 
complications. Treatments: 
daclatasvir (DCV) + sofosbuvir 
(SOF) vs. DCV + ribavarin (RBV) 
and pegalated interferon (pINF) 
+ RBV in treatment naïve and 
treatment experienced 
populations. Conclusion 
DCV+SOF safe and effective 
option and could be considered 
cost-effective following 
pINF+RBV treatment.  
Study 
supported the 
BMS product 
daclatasvir 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science. 
Qin et al 40 Overactive 
bladder with 
urge urinary 
incontinence 
Pfizer Inc Decision model to estimate 52-
week costs of initiating 
treatment with fesoterodine vs. 
no pharmacotherapy in 
vulnerable elderly population in 
a hypothetical health plan. OAB 
related costs included 
fesoterodine drug acquisition 
costs, healthcare resource use 
and OAB related co-
morbidities. Estimated cost 
saving of $1,616 per patient in 
US. 
Study 
supported the 
Pfizer product 
fesoterodine 
Claims presented 
are potentially 
evaluable. While 
the authors 
recommend 
future research 
no 
recommendation 
for  protocols to 
support claims 
assessment to 
meet required 
standards of 
normal science 
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Roze et al 41 Type 1 
diabetes 
Medtronic 
International 
Trading  
Application of IMS CORE 
diabetes model to project 
lifetime cost-effectiveness of 
sensor-augmented pump 
therapy (SAP) with a low 
glucose-suspend (LGS) feature 
vs. continuous subcutaneous 
infusion (CSII) plus self-
monitoring in a UK treating 
environment (SMBG). Study 
concludes that SAP+LGS likely 
to be cost-effective compared 
to CSII+SMBG. 
Study 
supported the 
Medtronic 
sensor 
augmented 
pump (SAP) 
product 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science. 
Usmani et al 42 Transplant 
ineligible 
patients with 
newly 
diagnosed 
multiple 
myeloma 
Celgene 
Corporation 
Lifetime partitioned survival 
model with 3 health states 
progression-free survival, post-
progression survival and dead 
to project lifetime, total direct 
costs, total life years (LY) and 
QALYs. Treatment: 
lenalidomide + dexamethasone 
(Rd) vs. bortezomib +melphalan 
+ prednisone (VMP) as initial 
treatment. Incremental cost 
per QALY and LY gained with Rd 
vs. VMP estimated $53,826 and 
$35,552 respectively. Rd may 
be a cost-effective alternative 
to VMP given oncology 
willingness-to-pay thresholds.   
Study 
supported the 
Celgene 
product 
lenalidiomide 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science. 
Vandewalle et al 
43 
Myelofibrosis Novartis A discrete state lifetime cohort 
model to compare impact on 
overall survival of ruxolitinib 
versus best available therapy 
(BAT) in a Portuguese 
treatment setting. Applying a 
Weibull parametric survival 
model a projected discounted 
(at 5%) median survival for 
ruxolitinib of 5.7 years vs 3.3 
years for BAT. Discounted 
incremental lifetime healthcare 
costs €97,052. At willingness to 
pay of €50,000 per life year 
probability of ruxolitinib being 
cost-effective against BAT was 
> 95%.    
Study 
supported the 
Novartis 
product 
ruxolitinib 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science. 
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Whalen et al 44 Chronic 
myelogenous 
leukemia 
Bristol Myers-
Squibb (BMS) 
Lifetime Markov model 
comparing dasatinib–initiated 
treatment sequences for 
patients failing imatinib 
compared to high dose imatinib 
and nilotinib. Dasatinib is 
associated with modeled 
increased survival and quality 
of life compared to high dose 
imatinib and to a smaller extent 
nilotinib. Respective ICER per 
QALY $170,00 and  $160,000.  
Study 
supported the 
BMS product 
dasatinib 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science. 
Francois et al 45 Neurogenic 
orthostatic 
hypotension 
Lundbeck A lifetime Markov model to 
predict the number of falls and 
treatment responses in 
neurogenic orthostatic 
hypotension (nOH) and the 
predicted impact of droxipoda 
to treat symptomatic nOH in 
patients with Parkinson’s 
disease vs. standard of care. 
Outcomes: projected number 
of falls, QALYs and direct costs. 
Droxipoda was cost-effective 
vs. standard of care with ICERs 
of $47,001/QALY gained, 
$24,866 per fall avoided with 
moderate/major industry and 
$1,559 per avoided fall with 
no/minor injury. Droxipoda a 
cost-effective option.      
Study 
supported the 
Lundbeck 
product 
droxipoda  
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
Quon et al 46 Recurrent 
venous 
thromboembo
lism 
Pfizer Canada Inc 
and Bristol-
Myers Squibb 
(BMS) Canada 
A lifetime Markov model 
following venous 
thromboembolism (VTE) 
patients in a Canadian treating 
environment. Extended 
treatment with apixaban 
compared to 
enoxaparin/warfarin. Modeled 
impact of apixaban associated 
with fewer recurrent VTEs, VTE-
related deaths and bleeding 
events and lowest overall cost 
compared to other NOAcs, but 
at slightly increased cost. 
Apixaban can offer substantial 
clinical benefits and is a cost-
effective alternative to 
enoxaparin/warfarin. 
Study 
supported the 
Pfizer/BMS 
product 
apixaban. 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
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Lopez-Belmonte 
et al 47 
Herpes zoster 
vaccination 
Sanofi Pasteur-
MSD 
Lifetime Markov model applied 
to Spanish population cohort 
50 years and over comparing 
vaccinated and non-vaccinated 
tracks. Vaccinating 30% of 
population resulted in QALY 
gains in range €30,000 to 
€50,000 range with new 
vaccine zostavax.  
Study 
supported the 
Sanofi 
Pasteur-MSD 
product 
zostavax 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
Perez-Ruiz et al 
48 
Hyperuricemia 
in gout 
Menarini Group A five-year Markov model of 
febuxostat vs allopurinol in 
sequential treatment of 
hyperuricemia in Spain. 
Addition of febuxostat to any 
therapeutic strategy was an 
efficient option with ICERs 
ranging from €5,268 to €9,737 
and below €30,000/QALY 
threshold. 
Study 
supported the 
Menarini 
Group product 
febuxostat 
Claims presented 
are potentially 
evaluable in a 
shorter 
timeframe 
Beauchemin et al 
49 
Advanced 
breast cancer 
Canadian 
Institutes for 
Health Research 
Application of Global 
Pharmacoeconomics of 
Metastatic Breast Cancer 
(GPMBC) Markov lifetime 
model of interventions in 
breast cancer.  
Not applicable Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
Goeree et al 50 Second-line 
advanced 
squamous 
non-small cell 
lung cancer 
(NSCLC) 
Bristol-Myers 
Squibb 
Lifetime progression free 
survival and Markov models 
applied to evaluating expected 
costs, outcomes and 
incremental cost-utility (QALYs) 
of docetaxel and erlotinib vs 
nivolumab for NSCLC in a 
Canadian treating environment. 
Nivolumab cost utility 
estimates were $152,229 and 
$141,836 respectively vs. 
docetaxel and erlotinib. 
Study 
provided 
qualified 
support for 
BMS product 
nivolumab 
Claims presented 
are potentially 
evaluable in a 
shorter 
timeframe 
Haig et al 51 Diabetic 
macular 
edema 
Novartis Pharma 
AG 
Lifetime Markov model to 
evaluate the impact of 
ranibizumab (RAN) 
monotherapy of combination 
therapy (RAN + laser 
photocoagulation) versus laser 
monotherapy for visual 
impairment due to diabetic 
macular edema (DME) in a 
Canadian treating environment. 
Building on a previous model 
long-term costs and outcomes 
followed 3 years of treatment 
with patients cycling between 8 
health states best-corrected 
visual acuity (BCVA) status. 
Given a Canadian ICER 
Study 
supported the 
Novartis AG 
product 
ranibizumab 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
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threshold of C$50,000 both 
RAN monotherapy and 
combination therapy were 
cost-effective compared to 
laser. 
Bruhn et al 52 Type 2 
diabetes 
GlaxoSmith Kline 
(GSK) 
Cost-utility assessment with the 
CORE diabetes model in a 50 
year timeframe to assess 
albiglutide against insulin 
lispro, insulin glargine and 
sitagliptin  
Study 
supported the 
GSK product 
albiglutide 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
Hernandez et al 
53 
Relapsing-
remitting 
multiple 
sclerosis 
Biogen A 10-year Markov cohort cost-
utility model to evaluate 
peginterferon beta-1a vs. 
interferon beta-1a and 
glatiramer acetate in a US 
treating environment. Over 10 
years peginterferon beta-1a 
was dominant when compared 
with interferon beta-1a and 
glatiramer.    
Study 
supported the 
Biogen 
product 
peginterferon 
beta-1a 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
Guerin et al 54 Mitral 
regurgitation 
Abbott Vascular A 5-year 4-state Markov model 
to evaluate efficacy of a 
MitraClip strategy vs. medical 
management in a French 
treating environment. Primary 
endpoint deaths avoided. Over 
5 years among a hypothetical 
cohort of 1000 patients, 276 
deaths avoided. Cost per 
dewath avoided €20,720.  
Study 
supported the 
Abbott 
Vascular  
product 
MitraClip 
Claims presented 
are potentially 
evaluable in a 
shorter 
timeframe 
Su et al 55 Relapsing-
remitting 
multiple 
sclerosis 
Biogen A lifetime Markov model with 
21 health states to evaluate 
delayed-release dimethyl 
fumarate (DMF) as first line 
treatment in a Canadian 
treatment environment vs. 
DMTs glatiramer acetate and 
rebif 44mcg. On traditional 
Canadian willingness-to-pay 
thresholds DMF a cost-effective 
option compared to other first 
line DMTs.  
Study 
supported the 
Biogen  
product DMF 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
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Rønborg et al 56 Dust mite 
respiratory 
allergic 
disease 
ALK Cost minimization comparison 
between Alutard SQ as 
standard of care and SQ SLIT-
tablet ACARIZAX. Direct and 
indirect annual cost savings 
with SQ-SLIT of approximately 
€1,000. 
Study 
supported the 
ALK product 
SQ-SLIT 
Claims presented 
are evaluable and 
replicable in a 
Danish treating 
environment and 
other countries 
(recommended as 
a therapy by 
Global Initiative 
for 
Asthma[GINA]) 
Roze et al 57  Type 2 
diabetes 
Medtronic 
International 
Trading  
Application of IMS CORE 
diabetes model to project 
lifetime cost-effectiveness of 
continuous subcutaneous 
insulin infusion (CSII) to achieve 
improved glycemic control  vs. 
optimization of basal bonus 
MDI therapy where patients 
still unable to achieve good 
glycemic control. ICER 
estimated at €62,895 per QALY 
gained and €60,474 per QALY 
with indirect costs included. As 
ICER below willingness-to-pay 
threshold of €80,000, CSII likely 
to represent good ‘value for 
money’ in poorly controlled 
type 2 diabetes patients.  
Study 
supported the 
Medtronic  
product CSII 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
Lee et al 58 Hepatocellular 
carcinoma 
Bayer Healthcare Decision model driven cost 
comparison of Gd-EOB-DTPA 
MRI vs., ECCM-MRI and multi-
detector computed 
tomography detection and 
characterization of liver lesions 
in Thai and Korean treating 
environments from payer and 
hospital perspectives. Input 
data estimated and validated 
by experts. Costs of diagnostic 
alternatives  and related 
treatment options from 
literature.. Conclusion: Gd-EOB-
DTPA-MRI gives better 
diagnostic certainty and cost 
savings.  
Study 
supported the 
Bayer  
contrast agent 
product Gd-
EOB-DTPA 
MRI 
Claims presented 
are potentially 
evaluable and 
replicable ina 
other treating 
environments 
and countries 
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Labotesis et al 59 Acute 
ischemic 
stroke 
Medtronic A lifetime Markov model to 
evaluate cost-effectiveness  in 
neurothrombectomy of stent-
retriever thrombectomy in 
combination with intravenous 
tissue-type plasminogen 
activator (IV t-PA) vs. IV t-PA 
alone. Combination therapy 
associated with improved 
quality of life, overall cost-
savings with higher treatment 
costs  offset by long-term cost 
savings. In a UK treatment 
environment net benefit of 
£79,402. Conclusion: combined 
therapy cost-effective in acute 
ischemic stroke.   
Study 
supported the 
Medtronic 
stent retriever 
product 
Solitaire 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
Saab et al 60 Genotypes 1 
or 4 hepatitis 
C 
AbbVie A lifetime Markov model of 
chronic hepatitis C  for both 
treatment naïve and 
experienced patients evaluated 
the cost-effectiveness of direct-
acting antiviral therapies  in a 
US treating environment. 
Outcomes modeled included 
rates of 
compensated/decompensated  
cirrhosis, heptacellular 
carcinoma, liver related 
deeaths, total costs, life-years 
and quality adjusted life years. 
Among the currently 
recommended treatments 
ombitasvir/paritaprevir/ritonav
ir + dasabuvir +/- ribavarin 
(3d+/-R) for GT1 and 
ombitasvir/paritaprevir/ritonav
ir + ribavarin (2D+R) for GT4 
had a favorable cost-
effectiveness profile. 
Study 
supported the 
AbbVie 
combination 
therapy 
products 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
Bianic et al 61 Liver 
transplants 
Novartis Pharma A lifetime Markov model with 
flexibility to allow for results 
over shorter time scales to 
compare cost-effectiveness of 
everolimus (EVR) plus reduced 
tacrolimus (TAC) vs. standard 
dose TAC in an Italian treating 
environment. Modeled ICERs 
favored the cost-effective 
combination EVR+TAC for both 
survival and quality of life.  
Study 
supported the 
Novartis  
product 
everolimus 
Claims presented 
are potentially 
evaluable in the 
short-term. 
Evaluable claims 
not presented. 
No 
recommendation 
for  protocols to 
support claims 
assessment to 
meet required 
standards of 
normal science 
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Einarson et al 62 Chronic 
schizophrenia 
Janssen 
Pharmaceuticals 
A 1-year decision model 
adapted to a Portguese 
environment to compare 
paliperidone palmitate (PP-LAI) 
to risperidone (RIS-LAI), 
haloperidol (HAL-LAI) and 
olanzapine (OLZ). Clinical and 
cost data from the literature. 
Outcomes: INCERs for copst-
utility and cost-effectiveness 
assessments. Results: PP-LAI 
dominated HAL-LAI and RIS-LAI 
and cost-effective over OLZ 
against NICE/Portuguese 
willingness-to-pay thresholds.  
 Claims presented 
are potentially 
evaluable in the 
short-term. 
Evaluable claims 
not presented. 
No 
recommendation 
for  protocols to 
support claims 
assessment to 
meet required 
standards of 
normal science 
Hurry et al 63 Anaplastic 
lymphoma 
kinase positive 
(ALK+) non-
small cell lung 
cancer  
Novartis 
Pharmaceuticals 
A 4-year partitioned survival 
model with three health states 
for cost-effectiveness of 
ceritinib vs pemetrexed, best 
supportive care and historical 
control (HC) in a Canadian 
treating environment for 
patients previously treated 
with crizotinib. Over 4 years 
ceritinib associated with gain 
0.86 QALYs and total direct 
costs of $89,740.ICER vs BSC 
$149,117, $80,100 vs 
permetrexed and $104,436 vs. 
HC. Ceritinib may be considers 
a cost-effective option. 
Study 
supported 
Novartis 
product 
ceritinib. 
Crizotinib also 
a Novartis 
product. 
Claims presented 
are potentially 
evaluable in the 
short-term. 
Evaluable claims 
presented over 4-
years.  
Johnson et al 64 Genotype 1 
hepatitis c 
virus 
infectionc 
AbbieVie A 70-year Markov model with 
1-year cycle and 6 health 
states. Modeled comparison 
ombitasvir/paritaprevir/ritonav
ir and dasabuvir+/-ribavarin 
(OMB/PTRV/r + DSV+/-RBV) 
versus regimens including 
pegylated interferon for 
treatment naïve/experienced in 
a UK treatment setting. 
Comparator regimens other 
than PegINF/RBV where ICERs 
per QALY were £13,864 and 
£10,258 respectively. 
Conclusion: product a cost-
effective oral treatment 
compared to standard 
treatment regimens in the 70-
year timeframe. 
Study 
supported 
AbbVie 
combination 
therapy 
products  
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
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Muduma et al 65 Liver 
transplant 
Astellas Pharma 
Europe Limited 
A 25-year Markov model to 
evaluate cost-utility of 
immunosuppressive regimens 
prolonged release (PR) 
tacrolimus, immediate release 
(IR) tacrolimus and ciclosporin 
in liver transplants in a UK 
treating environment. PR 
tacrolimus resulted in 
increased life expectancy and 
quality adjusted life expectancy 
relative to IR tacrolimus and 
ciclosporin.Overall, ICER of 
£1,889 per QALY gained. 
Study 
supported 
Astellas 
product 
tacrolimus PR  
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
Solon et al 66 Characterizati
on of 
diminutive 
colon polyps 
Olympus Europa Decision model with 7-year 
time horizon to model a cost-
consequences and budget 
impact analysis of narrow band 
imaging (NBI) vs. white light 
endoscopy (WLE) in a UK 
treating environment. NBI 
offered cost-savings within 
minimal impact on health 
outcomes and associated 
adverse events with annual 
cost savings of £141,192,057. 
Study 
supported 
Olympus NBI 
product  
Potential to 
reformulate 
claims for cost 
savings to make 
them evaluable in 
a shorter time 
frame. As stated 
do not meet 
required 
standards of 
normal science. 
Xuan et al 67  Newly 
diagnosed 
duodenal 
ulcer 
Livzon 
Pharmaceuticals 
Group Inc 
A literature-based one-year 
decision tree model to assess 
cost-effectiveness of 10mg 
once daily ilaprazole vs. once 
daily 20mg omeprazole in a 
China treatment environment. 
Ilaprazole was cost-effective 
with an ICER of Y132,056 which 
is within the WHO threshold of 
3 times per capita GDP. 
Study 
supported 
Livzon product 
ilaprazole 
Claims presented 
are potentially 
evaluable given 
timeframe of 
study 
Jakubowiak et al 
68 
Relapsed 
multiple 
myeloma 
Amgen Inc A lifetime partitioned survival 
model (the Kyprolis Global 
Economic Model-K-GEM) to 
assess the cost-effectiveness of 
carfilzomib-lenalidomide-  
dexamethasone (KRd) vs. 
lenalidomide-dexamethasone 
(Rd). KRd was estimated to be 
more effective than Rd in QALY 
gains and with an ICER of 
$107,520 per QALY. Assuming a 
willingness-to-pay threshold of 
$150,000 KRd may represent 
an efficient allocation of 
resources. 
Study 
supported 
Amgen 
product 
carfilzomib 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
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Chuang et al 69 Type 2 
diabetes  
AstraZeneca 
Pharmaceuticals  
Application of the Cardiff 
Diabetes Model with a 40-year 
time horizon to evaluate cost-
effectiveness of exenatide 
(EQW) vs. dulaglutide, 
liraglutide and lixisenatide in 
patients not adequately 
controlled on metformin.QALY 
gains ranged from 0.043 to  
0.102 aganst comparators.  
EQW dominated liraglutide. 
Cost per QALY gained £596, 
£1,004 and respectively. 
Probability EQW cost effective 
ranged from 76-99%.   
Study 
supported 
AstraZeneca 
product 
exenatide 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
Wielage et al 70 Overactive 
bladder 
Astellas Pharma 
Global 
Development 
Markov state-transition model 
with 3-year time horizon to 
assess mirabegron vs. six 
antimuscarinics in US Medicare 
Advantage and commercial 
perspectives. Primary outcome 
cost per QALY.  Costs per QALY 
respectively $$66,347 and 
$59,690. Product judged cost-
effective.   
Study 
supported 
AstraZeneca 
product 
exenatide 
Potential to 
reformulate 
claims to make 
them evaluable in 
a shorter time 
frame. As stated 
do not meet 
required 
standards of 
normal science. 
Virabhak et al 71  Chronic 
hepatitis C 
virus genotype 
1b 
AbbVie Lifetime Markov state 
transition model to compare 
ombitasvir/paritaporevir/ritona
vir (OBV/PTV/r) vs. 
daclatasvir+asunaprevir 
(DVC/ASV) and no treatment in 
patients without cirrhosis and 
OBV/PTV/r vs. DCV/ASV and 
sofosbuvir/ledipasvir (SOF/LDV) 
in Y93H mutation negative 
patients with and without 
cirrhosis in treatment 
naïve/experienced in a 
Japanese treatment 
environment. Results: 
OBV/PTV/r appears to be a 
cost-effective treatment 
against DCV/ASV and 
dominates no treatment 
without cirrhosis 
 
Study 
supported 
AbbVie 
combination 
therapy 
products 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
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Gordon et al 72 Type 2 
diabetes 
AstraZeneca Application of the Cardiff 
Diabetes Model with a 40 year 
time horizon  to evaluate cost 
effectiveness of exenatide BID 
vs. bolus insulin lispro (TID) as 
add on when glycemic control 
sub-optimal with titrated basal 
insulin glargine and metformin 
from a Swedish healthcare 
perspective. Results: exenatide 
BID associated with 
incremental cost of €1,270 and 
QALY increase of 0.64 
compared to lispro TID over 40 
years. Cost per QALY gained 
€1,971.  
Study 
supported 
AstraZeneca 
product 
exenatide 
Claims presented 
are non-evaluable 
and do not meet 
required 
standards of 
normal science 
Goeree & 
Goeree73 
 
 
Opioid 
induced 
constipation 
Purdue Pharma One-year cost-utility decision 
model  comparing combination 
oxycodone with naloxone 
versus oxycodone in managing 
moderate-to-severe pain in 
Canadian patients with opioid-
induced constipation. Costs 
offsets to analgesic costs 
resulted in 1-year cost utility of 
naloxone ranging from C$2178-
C$7,732 per QALY gained in 
base case analysis. 
Study 
supported  
Purdue 
Pharma 
product Targin 
Claims presented 
are potentially 
evaluable 
although no 
protocol 
presented for 
assessment in 
Canadian treating 
environment  
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